VYNE Therapeutics Inc.
VYNE Therapeutics Inc. (VYNE): 5 pipeline candidates · ~19 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
18.5 months
D/E 0.05 · 0% dilution
Lead: Phase 2
5 candidates
N/A
N/A
A transparent, data-derived signal for VYNE Therapeutics Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$21.3M
Cash
$24.6M
Quarterly Burn
$4.1M
Runway
18.5 mo
Revenue
$86K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| repibresib | Phase 2 |
| vehicle gel | Phase 2 |
| vyn201 | Phase 2 |
| vyn201 gel | Phase 2 |
| vyn202 | Phase 1 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
40
Total value held
$4.3M
| Holder | Shares | Value |
|---|---|---|
| lynx1 capital management lp | 1,628,700 | $973K |
| adar1 capital management, llc | 1,063,899 | $636K |
| braidwell lp | 916,077 | $547K |
| vanguard capital management llc | 529,114 | $316K |
| citadel advisors llc | 514,443 | $307K |
| kvp capital advisors, lp | 500,551 | $299K |
| two sigma investments, lp | 426,412 | $255K |
| geode capital management, llc | 322,711 | $193K |
| ikarian capital, llc | 264,912 | $158K |
| vanguard fiduciary trust co | 183,443 | $110K |
Showing top 10 of 40 institutional holders of VYNE Therapeutics Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in VYNE Therapeutics Inc.'s pipeline?
VYNE Therapeutics Inc. (VYNE) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is VYNE Therapeutics Inc.'s lead drug candidate?
VYNE Therapeutics Inc.'s most advanced tracked candidate is repibresib (Phase 2) for nonsegmental vitiligo (NSV).
What is VYNE Therapeutics Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, VYNE Therapeutics Inc. has approximately 18.5 months of cash runway.
What is VYNE Therapeutics Inc.'s market capitalization?
VYNE Therapeutics Inc.'s market capitalization is approximately $21.3M.
Who is the CEO of VYNE Therapeutics Inc.?
Mr. David T. Domzalski is the chief executive officer of VYNE Therapeutics Inc. (VYNE).
Get the full picture on VYNE Therapeutics Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.